Abstract
Results
Thirty-two trials (3,544 patients) were included. Compared to dopamine (866 patients, 450 events), norepinephrine (832 patients, 376 events) was associated with decreased allcause mortality, RR 0.89 (95% CI 0.81-0.98), corresponding to an absolute risk reduction of 11% and number needed to treat of 9. Norepinephrine was associated with lower risk for major adverse events and cardiac arrhythmias compared to dopamine. No other mortality benefit was demonstrated for the comparisons of norepinephrine to epinephrine, phenylephrine and vasopressin / terlipressin. Hemodynamic data were similar between the different vasopressors, with some advantage for norepinephrine in central venous pressure, urinary output and blood lactate levels.
Introduction
Septic shock and severe sepsis are a grave consequence of infection. Septic shock accounts for about 9% of admissions, and is the most common cause of death in intensive care units (ICUs) [1, 2] . The mortality rate reported is 40 to 60% [1, 3] . Septic shock is defined by the ACCP/ SCCM as the need for vasopressors to reverse sepsis-induced hypotension [4] . The concept of "early goal directed therapy" was developed in order to set early hemodynamic goals. The goals include central venous or mixed venous saturation (ScvO 2 ) higher than 70%, mean arterial pressure (MAP) 65 mmHg, central venous pressure (CVP) > 8-12 mmHg, and urine output > 0.5 ml/kg/hr within 6 hours of initiation of therapy [5] . Later the concept of lactate clearance was added to the goals as an alternative or addition to the ScvO 2 [6] . Thus, hemodynamic outcomes are regarded as surrogate markers for survival, the ultimate goal of treatment.
No study to date has demonstrated a statistically significant survival benefit of one vasopressor over another. Therefore, the choice of vasopressor in septic shock is rather empiric. The Surviving Sepsis Campaign recommends norepinephrine or dopamine as the first-choice vasopressor agent followed by epinephrine in patients who respond poorly to dopamine or norepinephrine [7, 8] .
In this systematic review we aimed to examine the evidence on the relative clinical, hemodynamics and safety of any vasopressors in the treatment of septic shock, in order to guide future trials and treatment guidelines.
Methods

Inclusion criteria
Randomized controlled trials (RCTs) and randomized crossover trials regardless of publication status were included. We included trials assessing adult patients with septic shock and sepsis with multiple organ dysfunction syndrome diagnosed using established criteria [4] , or an accepted definition of severe sepsis and end organ damage caused by hypoperfusion. In studies that recruited patients with shock due to many causes, we extracted data for septic patients where possible. The intervention assessed was vasopressor versus a different vasopressor, a combination of vasopressors, placebo or no vasopressor. The following vasopressors were included: dopamine, norepinephrine, epinephrine, phenylephrine, vasopressin and terlipressin.
We regarded vasopressin and terlipressin as non-adrenergic vasopressors. Trials that added open-label vasopressor(s) were included if it was applied to both arms of intervention. Studies comparing interventions limited to inotrope agents were excluded. We excluded studies that assessed different dosages or schedules of the same vasopressors.
Outcomes assessed
The primary outcome was all-cause mortality at 28 days following randomization, or when lacking these data, all-cause mortality as reported by the authors. Secondary outcomes included length of ICU stay and / or hospital stay in patients discharged alive; ventilator free days; vasopressor free days; hemodynamic profiles of patients at the first hour (or first measuring point), and at the 6 th hour (or second measuring point); and adverse events (AEs) (major AEs, arrhythmias, myocardial infarction, stroke, internal organ ischemic damage, and local extravasation or skin necrosis). The hemodynamic profile consisted of CVP, MAP, ScvO 2 , urinary output, blood lactate levels, cardiac index (CIX), systemic vascular resistance index (SVRI), heart rate, and oxygen delivery index (VIO 2 ); we also collected measurements of splanchnic blood flow, oxygen delivery, oxygen consumption and visceral CO 2 difference as measured by catheter sampling or tonometry. In studies that allowed crossover between arms, we included data regarding the first randomization only, if available. Mortality was not extracted from crossover studies. Outcome measures were collected on an intention-to-treat basis. Where such data was not presented, per-protocol results were used. We also compared results for adrenergic vasopressors versus non-adrenergic vasopressors.
Search methods
We searched MEDLINE, CENTRAL, LILACS and conference proceedings (International Symposium on Intensive Care and Emergency Medicine), up to June 2014. We also hand-searched all references of included studies, and previous meta-analyses for more trials. The words "vasopressor" and vasopressor names and their MESH terms were crossed with the terms "hypotension", "circulatory failure", "shock", "sepsis" or "bacteremia" and with the Cochrane highly sensitive filter for RCTs [9] . No language restrictions were used. Authors were contacted to complement data by e-mail and phone calls.
Data collection
Two reviewers independently inspected each reference identified by the search, scanned fulltexts of relevant studies, applied the inclusion criteria and extracted the data. Disagreements in data extraction were resolved by discussion with a third reviewer. Risk of bias was assessed in duplicate using domain-based evaluation, classifying studies primarily according to the risk of non-random allocation of patients to the intervention arm, i.e. allocation concealment and sequence generation. These were graded as adequate, unclear and inadequate as recommended in The Cochrane Handbook [9] . Additional domains assessed included blinding, incomplete outcome data reporting, ethics committee, patient consent and industrial sponsorship.
Data analysis
For binary data, individual study results are expressed as RR with 95% CI. For continuous outcomes we extracted end-value means with standard deviations (SD), as data for change from baseline was unavailable. In studies that reported median with interquartile ranges, we converted the reported values to means assuming a normal distribution [10] . RRs and mean differences were pooled using a fixed effect model (Mantel-Haenszel method) (Review Manager [RevMan], version 5.3 for Windows, The Cochrane Collaboration, Oxford, UK). Heterogeneity was defined by a chi-square test of heterogeneity <0.1 or an I 2 measure of inconsistency >40%. If significant heterogeneity was identified, we used random effect model (REM). We explored potential sources of heterogeneity: trials published before versus after the year 2004 (surviving sepsis campaign), trials conducted in developed versus developing countries, and the adequacy of allocation concealment and blinding
Results
The search yielded 2,380 publications of which 61 were potentially relevant. Thirty-six studies were excluded (Fig 1) , and 7 studies were added from reference hand searching. Altogether, 32 studies were included (all published in peer-review journals). The trials were published in the years 1989-2012 and recruited 3,544 patients (median 50 patients, Table 1 for trials' characteristics). Five trials were crossover [16] [17] [18] 37, 41] and the remaining were parallel RCTs. The comparisons assessed in included trials are summarized in Fig 2. The main comparisons were between norepinephrine and dopamine (14 trials, including 2 crossover trials) and norepinephrine and epinephrine (7 trials including 3 crossover trials). One trial compared vasopressin to placebo [24] ; Additional open-label vasopressors could be added to both study arms equally in 16/32 trials (Fig 2) . Eight trials were designed to measure clinical endpoints as the primary outcome, while 26 trials, including all crossover trials, measured hemodynamic data (crossover time at 45-220 minutes). The follow up duration was not stated in 21/32 trials; When stated, follow-up ranged from length of the ICU stay (3 trials) to 90 days (median 28 days). The common sources of infection were respiratory (34.6% of included patients) and intra-abdominal (25.1%). Steroid administration was reported in 5 studies, and given to 31-100% of all patients (median 74%), ( Table 1 ). The amount of fluids that was given for the resuscitation was reported in 7/32 trials and varied considerably (median 150 ml/hr, range 45-300 ml/hr). Another 10 trials reported a protocol based fluid resuscitation and titration by CIX. The weighted mean all-cause mortality was 45.0% (SD 16.2%, range 16.7-88.7%) and was not significantly correlated with publication year (Spearman's rho -0.260, p = 0.24, 32 studies, Table 1 ).
Risk of bias assessment
Risk of bias assessment is detailed in Table 2 . Low risk sequence generation and allocation concealment were reported in 16/32 (50%) and 13/32 (40.6%) trials, respectively. One study was 
Primary outcome
Mortality was reported in eleven trials that compared norepinephrine to dopamine. Funnel plot did not detect high risk of publication bias (S1 Fig) . Norepinephrine was associated with reduced all-cause mortality (RR 0.89, 95% CI 0.81-0.98, I 2 = 0%), corresponding to an absolute risk reduction of 11% and number needed to treat of 9 (Fig 3) . Excluding De Backer's study from 2010 [15] which contributed 64% of the weight, did not alter the results, RR 0.84 (95% CI 0.70-0.99, I 2 = 0%, n = 10), as the exclusion of other trials. Sensitivity analysis restricted to trials from the developed world, trials published after 2004, trials with adequate allocation concealment and generation and blinding did not alter this result. Analysis based on trials whose primary outcome was clinical [15, 33, 42] revealed the same trend for reduced mortality with norepinephrine that was not statistically significant (RR 0.91 95% CI 0.82-1.02). There was no statistically significant mortality benefit with norepinephrine over epinephrine (RR 0.96, 95% CI 0.77-1.21, I 2 = 0%, n = 4). Excluding one trial that did not add dobutamine to norepinephrine did not alter the results (RR 0.89, 95% CI 0.69-1.14, I 2 = 0%, n = 3).
There was no statistically significant mortality benefit with norepinephrine over vasopressin / terlipressin RR 1.07 (95% CI 0.91-1.26, I 2 = 0%, n = 5), and over phenylephrine RR 0.92 (95% CI 0.64-1.32, I 2 = 0%, n = 2). Results for the comparison of dopamine to terlipressin, and vasopressin to placebo were not pooled (one trial for each comparison, no change in mortality ratio within each trial). When compared to all other treatments, norepinephrine and vasopressin were not associated with a benefit in mortality (RR 0.96, 95% CI 0.86-1.04, I 2 = 0%, n = 16, and RR 1.01, 95% CI 0.88-1.15, I 2 = 14%, n = 8, respectively). Comparing adrenergic to Fig 4) . Arrhythmias, were significantly decreased with norepinephrine compared to dopamine, RR 0.48 (95% CI 0.40-0.58, I 2 = 30%, n = 4, Fig 4) . Compared with vasopressin / terlipressin, norepinephrine was not associated with a statistically significant change in major AEs and arrhythmias. Due to lack of reported data, we did not pool other AEs separately. Data for AEs with epinephrine and phenylephrine was sparse and did not allow pooled meta-analysis. Hemodynamic data-ScvO2, urinary output, lactate clearance, MAP, CVP. Forest plots of the presented data are available as Supporting Information (S2 Fig). Clinical and hemodynamic measurements at the beginning of the interventions, varied significantly between the trials (S1 Table) . No vasopressor had a statistically significant effect of the MAP at any measurement point, compared to other vasopressor. CVP was higher with norepinephrine at the Oxygen delivery index in the first measuring point were decreased with norepinephrine compared to other vasopressors by a mean of 14.06 ml/min/m 2 (95% CI 0.16-27.9, I 2 = 59%, REM, n = 10). First measuring point splanchnic CO 2 difference was lower with norepinephrine in comparison to epinephrine by a mean difference of 3.74 (95% CI 1.82-5.66, I 2 = 42%, REM, n = 4). There were insufficient data to compare vasopressors with regard to splanchnic blood flow and splanchnic oxygen delivery index.
Discussion
The pooled evidence summarized in this meta-analysis shows absolute reduction of 11% in 28-days all-cause mortality with norepinephrine compared with dopamine corresponding to number needed to treat of 9. Dopamine resulted in more than twice the risk for major AEs including a twofold increase in the risk for cardiac arrhythmias. The hemodynamic profile of norepinephrine was also more favorable than the other vasopressors, resulting in decreased lactate levels, increased CVP and urine output in comparison to the other vasopressors. Further benefits of norepinephrine included reduced CIX and heart rate, elevated SVRI and reduced VIO 2 and splanchnic CO 2 difference. We did not demonstrate mortality benefit with norepinephrine over epinephrine, phenylephrine and vasopressin / terlipressin or between the other comparisons, although a trend towards reduced mortality with norepinephrine was seen in all comparisons. Clinical outcomes other than mortality were seldom reported and therefore it was not possible to get strong evidence for length of ICU / hospital stay and ventilator / vasopressor free days. AEs were also reported only by 15/32 trials. The lower rates of cardiac arrhythmia and major AEs with norepinephrine compared to dopamine might account for the reduced mortality rates observed with norepinephrine.
Data regarding clinical and hemodynamic measurement were sparse and inconsistent in methodology and time of report. Although considered as targets for early goal directed therapy, most trials did not report on the variables included in the algorithm (including both studies that were published before and after 2004 with the publication of the surviving sepsis campaign [8] ). The concept of early goal directed therapy was challenged recently in a large RCT [43] , in which no mortality benefit with protocol based resuscitation was observed compared with usual care. Thus, obtaining the predefined hemodynamic goal with either vasopressor may not be translated to any clinical outcome change.
No statistically significant changes were observed between vasopressin / terlipressin and all adrenergic vasopressors (norepinephrine, dopamine) regarding mortality and AEs. One of the rationales for the use of non-adrenergic vasopressors is relative vasopressin deficiency in patients with septic shock [44] and the hypothesis that vasopressin can reduce the need for catecholamines and AEs associated with adrenergic stimulation. We did not observe a reduction in AEs, but most patients in the vasopressin arm received norepinephrine at randomization and at least for a part of the trial period as open-label vasopressor.
The use of vasopressors and inotropes for several conditions were addressed previously in systematic reviews and meta-analysis. A Cochrane systematic review [45] assessed the efficacy of vasopressors for the treatment of any circulatory failure in RCTs. The authors did not pool results for studies assessing septic patients alone. No mortality benefit was demonstrated for all direct comparisons between different vasopressors or vasopressor combinations. Dopamine was associated with more arrhythmias. Another review [46] , focused only on the comparison of norepinephrine and dopamine in septic shock, but included observational studies as well as randomized controlled trials. It showed an advantage of norepinephrine over dopamine with regard to 28 days, all-cause mortality, RR for increased mortality with dopamine 1.12 (95% CI 1.01-1.20, I 2 = 0%, n = 6). Vasu et al. [47] assessed norepinephrine and dopamine in septic shock, however the data quoted from the largest trial were inaccurate [15] , thus introducing further bias. Several limitations of this review should be noted. Included trials span a long period, starting before 1989 and the last published in 2012. During this period advances in support and early goal directed treatment had been introduced to improve the quality of care in ICU. However, mortality rates were unchanged from early to recent trials (weighted mean crude mortality rate 45.0%). We could not perform a meta-analysis of differences from baseline for the hemodynamic measures, which might be more easily interpreted than end values, because results were not reported as such. An individual patient data meta-analysis might provide a better understanding of the evidence accrued to date. To note, most of the trials were methodologically good or very good, however the treatment algorithm were different in regard to dosages, time to events and monitoring. The trials were diverse in reporting and statistical methods.
Future trials should use a uniformly acceptable protocol consisting of adequate methodological design, a common sepsis management algorithm (including the use of fluid resuscitation, stress dose steroids and initial hemodynamic targets). The reported outcomes should include all-cause mortality and, for patients discharged alive, length of hospital or ICU stay, length of ventilation, length of vasopressor support and AEs.
Conclusion
These data supply further support for the use of norepinephrine over dopamine for the treatment of patients with septic shock in ICUs, given consistent reduced all-cause mortality at 28 days with supporting hemodynamic data and lower rate of major AEs and cardiac arrhythmias. This recommendation is based on data from all the RCTs published up to date, with no heterogeneity. Trials to guide recommendations for the use other vasopressors, especially non-adrenergic, are needed.
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